Cargando…

Broadly neutralizing monoclonal antibodies for HIV prevention

INTRODUCTION: The last 12 years have seen remarkable progress in the isolation and characterization of at least five different epitope classes of HIV‐specific broadly neutralizing antibodies (bnAbs). Detailed analyses of these bnAb lineages, maturation pathways and epitopes have created new opportun...

Descripción completa

Detalles Bibliográficos
Autores principales:	Miner, Maurine D., Corey, Lawrence, Montefiori, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Supplement: Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8606861/ https://www.ncbi.nlm.nih.gov/pubmed/34806308 http://dx.doi.org/10.1002/jia2.25829

Ejemplares similares

Pharmacokinetics and Immunogenicity of Broadly Neutralizing HIV Monoclonal Antibodies in Macaques
por: Rosenberg, Yvonne, et al.
Publicado: (2015)

Strategies for induction of HIV‐1 envelope‐reactive broadly neutralizing antibodies
por: Williams, Wilton B., et al.
Publicado: (2021)

Rapid High-Level Production of Functional HIV Broadly Neutralizing Monoclonal Antibodies in Transient Plant Expression Systems
por: Rosenberg, Yvonne, et al.
Publicado: (2013)

One Against All: A Broadly Influenza Neutralizing Man-made Monoclonal Antibody Passes Phase I
por: Saelens, Xavier
Publicado: (2016)

Incomplete Neutralization and Deviation from Sigmoidal Neutralization Curves for HIV Broadly Neutralizing Monoclonal Antibodies
por: McCoy, Laura E., et al.
Publicado: (2015)

Broadly Neutralizing Antibodies for HIV-1 Prevention
por: Walsh, Stephen R., et al.
Publicado: (2021)

An in vitro methodology for discovering broadly-neutralizing monoclonal antibodies
por: Ahmadi, Shirin, et al.
Publicado: (2020)

Modeling Neutralization Kinetics of HIV by Broadly Neutralizing Monoclonal Antibodies in Genital Secretions Coating the Cervicovaginal Mucosa
por: McKinley, Scott A., et al.
Publicado: (2014)

Structural Basis for Broad HIV-1 Neutralization by the MPER-Specific Human Broadly Neutralizing Antibody LN01
por: Pinto, Dora, et al.
Publicado: (2019)

Importance of neutralization sieve analyses when seeking correlates of HIV-1 vaccine efficacy
por: Montefiori, David C
Publicado: (2014)

Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques
por: Shingai, Masashi, et al.
Publicado: (2014)

Broad neutralization of SARS-related viruses by human monoclonal antibodies
por: Wec, Anna Z., et al.
Publicado: (2020)

Eliciting broadly neutralizing antibodies against HIV-1 that target gp41 MPER
por: Han, D, et al.
Publicado: (2012)

Dose–response curve slope helps predict therapeutic potency and breadth of HIV broadly neutralizing antibodies
por: Webb, Nicholas E., et al.
Publicado: (2015)

Meeting report: South African Medical Research Council Standard of Care in Clinical Research in Low- And Middle-Income Settings Summit, November 2017
por: Miner, Maurine D., et al.
Publicado: (2021)

Broadly Neutralizing Antibodies for HIV Eradication
por: Stephenson, Kathryn E., et al.
Publicado: (2016)

Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection
por: Wagh, Kshitij, et al.
Publicado: (2016)

Potential of conventional & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections
por: Wagh, Kshitij, et al.
Publicado: (2018)

Retraction: eliciting broadly neutralizing antibodies against HIV-1 that target gp41 MPER
por: Han, D, et al.
Publicado: (2014)

Clinical Trials of Broadly Neutralizing Monoclonal Antibodies for Human Immunodeficiency Virus Prevention: A Review
por: Mahomed, Sharana, et al.
Publicado: (2020)

A Derivative of the D5 Monoclonal Antibody That Targets the gp41 N-Heptad Repeat of HIV-1 with Broad Tier-2-Neutralizing Activity
por: Rubio, Adonis A., et al.
Publicado: (2021)

Structural basis for broad sarbecovirus neutralization by a human monoclonal antibody
por: Tortorici, M. Alejandra, et al.
Publicado: (2021)

Optimizing clinical dosing of combination broadly neutralizing antibodies for HIV prevention
por: Mayer, Bryan T., et al.
Publicado: (2022)

Human Monoclonal Antibodies Broadly Neutralizing against Influenza B Virus
por: Yasugi, Mayo, et al.
Publicado: (2013)

Insensitivity of Paediatric HIV-1 Subtype C Viruses to Broadly Neutralising Monoclonal Antibodies Raised against Subtype B
por: Gray, Elin Solomonovna, et al.
Publicado: (2006)

Genetic Signatures in the Envelope Glycoproteins of HIV-1 that Associate with Broadly Neutralizing Antibodies
por: Gnanakaran, S., et al.
Publicado: (2010)

A broadly neutralizing macaque monoclonal antibody against the HIV-1 V3-Glycan patch
por: Wang, Zijun, et al.
Publicado: (2020)

Estimating the epidemic consequences of HIV prevention gaps among key populations
por: Mishra, Sharmistha, et al.
Publicado: (2021)

HIV vaccine development and broadly neutralizing antibodies
por: Greenspan, Neil S., et al.
Publicado: (2015)

The expanding array of HIV broadly neutralizing antibodies
por: McCoy, Laura E.
Publicado: (2018)

A tale of two cascades: promoting a standardized tool for monitoring progress in HIV prevention
por: Auerbach, Judith D, et al.
Publicado: (2020)

Broadly neutralizing monoclonal antibodies protect against multiple tick-borne flaviviruses
por: VanBlargan, Laura A., et al.
Publicado: (2021)

Application of the SLAPNAP statistical learning tool to broadly neutralizing antibody HIV prevention research
por: Williamson, Brian D., et al.
Publicado: (2023)

A broadly neutralizing monoclonal antibody induces broad protection against heterogeneous PRRSV strains in piglets
por: Zhang, Zhigang, et al.
Publicado: (2021)

Shifts in UNAIDS ethics guidance and implications for ethics review of preventive HIV vaccine trials
por: Slack, Catherine, et al.
Publicado: (2021)

Maternal Broadly Neutralizing Antibodies Can Select for Neutralization-Resistant, Infant-Transmitted/Founder HIV Variants
por: Martinez, David R., et al.
Publicado: (2020)

Anti-V3 Monoclonal Antibodies Display Broad Neutralizing Activities against Multiple HIV-1 Subtypes
por: Hioe, Catarina E., et al.
Publicado: (2010)

Characterizing the fitness cost of viral escape from the HIV-1 broadly neutralizing monoclonal antibody VRC01
por: Lynch, RM, et al.
Publicado: (2012)

Characterization of Co-Formulated High-Concentration Broadly Neutralizing Anti-HIV-1 Monoclonal Antibodies for Subcutaneous Administration
por: Sharma, Vaneet K., et al.
Publicado: (2020)

Wide Prevalence of Heterosubtypic Broadly Neutralizing Human Anti–Influenza A Antibodies
por: Sui, Jianhua, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_iags41u5vipimemmbkdjn1dnub